Korea’s Celltrion Seeks New Trial Design For Rituxan Biosimilar Phase III
This article was originally published in PharmAsia News
Executive Summary
Celltrion says it will launch Phase III trials in the second half of 2013 with a new design, after completing a Phase I trial this month.